PMCB

$0.34+9.60%visit website

PharmaCyte Biotech, Inc.

Market Cap

$4M

Live price × SEC shares (Sep 11, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.77

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jul 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

0.1

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q2 FY2026 Oct 31, 2025	Q3 FY2026 Jan 31, 2026	Q4 FY2026 Apr 30, 2026	Q1 FY2027 Jul 31, 2026	TTM Jul 31, 2026
Revenue	0.00	0.00	0.00	0.00	0.00
Research & development	141	93	62	60	356
Total operating expenses	1,376	2,118	2,511	1,007	7,012
Operating income	(1,376)	(2,118)	(2,511)	(1,007)	(7,012)
Income tax				0.00
Net income	(7,418)	747	(4,393)	(5,081)	(16,146)
EPS (basic) ($)	(1.24)	(0.17)		(0.54)	—
EPS (diluted) ($)	(1.24)	(0.17)		(0.54)	—
Weighted avg. shares (basic)	6,796	9,263		10,736
Weighted avg. shares (diluted)	6,796	9,263		10,736

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Sep 14, 2026, period ended Jul 31, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jul 2010, with Tormere Pro.

Corporate Events (8-K)

4 filings in 12 months · 2 with priority itemsFull history →

Filed	Items	Filing
Oct 16, 2026 accepted 9:00 PM ET	4.01Auditor change	Document SEC ↗
Apr 2, 2026 accepted 8:19 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
Dec 5, 2025 accepted 10:00 PM ET	3.01Delisting notice	Document SEC ↗
Nov 18, 2025 accepted 9:05 PM ET	8-K/A 9.01Exhibits	Document SEC ↗
Oct 31, 2025 accepted 8:05 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
Sep 5, 2025 accepted 8:05 PM ET	1.01Material agreement2.01Acquisition / disposition7.01Reg FD disclosure	Document SEC ↗
Aug 18, 2025 accepted 1:20 PM ET	1.01Material agreement3.02Unregistered equity sale7.01Reg FD disclosure	Document SEC ↗
Apr 24, 2025 accepted 8:47 PM ET	5.07Shareholder vote	Document SEC ↗
Feb 26, 2025 accepted 6:57 PM ET	4.01Auditor change	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

36%

W/W +1.2pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

No Form 4 transactions on record.

Recent News

PharmaCyte Biotech(PMCB) Stock Options Chain | Quotes & News

Moomoo · 2026-10-31

PharmaCyte Biotech (PMCB) Ticks Up 5.45% to $0.36 as Micro-Cap Presses Against Resistance - AD Line Divergence

https://www.siam.in/ · 2026-10-28

PMCB Stock Jumps 25% After Company Sells Stake In Femasys

Stocktwits · 2025-11-25

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug

Stocktwits · 2025-11-25

symbol__ Stock Quote Price and Forecast

CNN · 2024-01-04

PMCB Stock Price and Chart — NASDAQ:PMCB

TradingView · 2021-08-11

Pharmacyt Biotch Stock Price Forecast. Should You Buy PMCB?

StockInvest.us · 2020-12-01

PharmaCyte Biotech, Inc. (PMCB) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2017-05-20

Informational purposes only, not investment advice.

Corporate Events (8-K)

4 filings in 12 months · 2 with priority itemsFull history →

Filed	Items	Filing
Oct 16, 2026 accepted 9:00 PM ET	4.01Auditor change	Document SEC ↗
Apr 2, 2026 accepted 8:19 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
Dec 5, 2025 accepted 10:00 PM ET	3.01Delisting notice	Document SEC ↗
Nov 18, 2025 accepted 9:05 PM ET	8-K/A 9.01Exhibits	Document SEC ↗
Oct 31, 2025 accepted 8:05 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
Sep 5, 2025 accepted 8:05 PM ET	1.01Material agreement2.01Acquisition / disposition7.01Reg FD disclosure	Document SEC ↗
Aug 18, 2025 accepted 1:20 PM ET	1.01Material agreement3.02Unregistered equity sale7.01Reg FD disclosure	Document SEC ↗
Apr 24, 2025 accepted 8:47 PM ET	5.07Shareholder vote	Document SEC ↗
Feb 26, 2025 accepted 6:57 PM ET	4.01Auditor change	Document SEC ↗